Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 148,768
  • Shares Outstanding, K 187,271
  • Annual Sales, $ 0 K
  • Annual Income, $ -148,700 K
  • EBIT $ -105 M
  • EBITDA $ -98 M
  • 60-Month Beta 1.89
  • Price/Sales 72.38
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.64
  • Most Recent Earnings $-0.14 on 11/12/25
  • Next Earnings Date 03/27/26 [BMO]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 198.37% (+23.19%)
  • Historical Volatility 106.78%
  • IV Percentile 92%
  • IV Rank 39.54%
  • IV High 366.53% on 03/09/26
  • IV Low 88.42% on 07/03/25
  • Expected Move (DTE 23) 0.3230 (40.89%)
  • Put/Call Vol Ratio 0.68
  • Today's Volume 1,139
  • Volume Avg (30-Day) 1,069
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 78,950
  • Open Int (30-Day) 84,292
  • Expected Range 0.4670 to 1.1130

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.13
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7010 +18.39%
on 03/20/26
1.3100 -36.65%
on 03/10/26
-0.3301 (-28.46%)
since 02/25/26
3-Month
0.7010 +18.39%
on 03/20/26
1.3100 -36.65%
on 03/10/26
-0.2501 (-23.16%)
since 12/24/25
52-Week
0.7010 +18.39%
on 03/20/26
2.9300 -71.68%
on 06/06/25
-2.0451 (-71.13%)
since 03/25/25

Most Recent Stories

More News
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 0.8153 (+2.63%)
Payroll Figures Due in Canada Next Week

Monday Economic Lookahead Construction spending (delayed report) (Jan.) Featured Earnings ...

CNM : 49.50 (-2.14%)
HUMA : 0.8153 (+2.63%)
CNTA : 28.61 (+2.58%)
AIR : 118.00 (+9.45%)
IMMX : 8.95 (+4.43%)
SA : 26.97 (+3.97%)
CDZI : 4.98 (+3.32%)
SFD : 25.32 (+3.43%)
AGX : 439.22 (-1.26%)
LXEO : 5.89 (+7.09%)
PAYX : 93.35 (+3.02%)
SBC : 3.86 (unch)
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia

DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 0.8153 (+2.63%)
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results...

HUMA : 0.8153 (+2.63%)
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval -  - Preparation is underway for expansion of Symvess ...

HUMA : 0.8153 (+2.63%)
Humacyte To Participate in Upcoming Investor Conferences

DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 0.8153 (+2.63%)
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting

- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society -  - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage,...

HUMA : 0.8153 (+2.63%)
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 0.8153 (+2.63%)
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

- Data is from comprehensive review of hospital charges and all-payer claims over five years -  - Preventable complications such as amputation and conduit infection increased initial hospital charges...

HUMA : 0.8153 (+2.63%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 0.9361
2nd Resistance Point 0.8981
1st Resistance Point 0.8462
Last Price 0.8153
1st Support Level 0.7563
2nd Support Level 0.7183
3rd Support Level 0.6664

See More

52-Week High 2.9300
Fibonacci 61.8% 2.0785
Fibonacci 50% 1.8155
Fibonacci 38.2% 1.5525
Last Price 0.8153
52-Week Low 0.7010

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.